Enveric Biosciences has received a second Notice of Allowance from the United States Patent and Trademark Office for its EVM401 Series. This patent covers novel, non-hallucinogenic mescaline derivatives designed to modulate neurotransmitters relevant to neuropsychiatric disorders. The compounds are inspired by methylone but are structurally differentiated to ensure strong intellectual property protection. This advancement strengthens Enveric's position in developing neuroplastogenic small-molecule therapeutics aimed at treating mental health disorders such as PTSD. Further preclinical testing is anticipated to assess the safety and efficacy of these compounds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.